Nuvalent, Inc. NUVL
$123.39
▼ -0.16% 24H
About
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for patients with cancer. The company applies structure-based drug design and chemistry expertise to create small-molecule treatments aimed at clinically proven kinase targets, with an emphasis on improving s…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees234
TickerNUVL
Statistics
Market Cap$9.73B
Revenue (TTM)$0
Net Income-$425.4M
Net Margin—
EPS$-5.85
P/E-21.06
P/S—
P/B8.29
EV/EBITDA-20.41
ROE-41.2%
Dividend Yield—
Price$123.39
Data: Twelve Data · Revenue = mcap / P/S